{"name":"Trevena","slug":"trevena","ticker":"TRVN","exchange":"NASDAQ","domain":"trevena.com","description":"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.","hq":"King of Prussia, PA","founded":2006,"employees":"23","ceo":"Carrie Bourdow","sector":"Pain / Opioid Innovation","stockPrice":0.01,"stockChange":0,"stockChangePercent":0,"marketCap":"$9,501","metrics":{"revenue":546000,"revenueGrowth":57.2,"grossMargin":-190.5,"rdSpend":16333000,"netIncome":-40289000,"cash":32975000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2020-01-01","label":"Olinvyk first approved","drug":"Olinvyk","drugSlug":"oliceridine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Olinvyk patent cliff ($0.XB at risk)","drug":"Olinvyk","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Olinvyk","genericName":"OLICERIDINE","slug":"oliceridine","indication":"Moderate pain","status":"marketed"}]}],"pipeline":[{"name":"Olinvyk","genericName":"OLICERIDINE","slug":"oliceridine","phase":"marketed","mechanism":"Olinvyk works by binding to the mu-type opioid receptor in the brain, which helps to reduce the perception of pain.","indications":["Moderate pain","Severe pain"],"catalyst":""}],"recentEvents":[{"date":"2022-02-22","type":"regulatory","headline":"Olinvyk Receives FDA Approval for the Management of Moderate to Severe Acute Pain","summary":"Trevena announced that the FDA approved Olinvyk (oliceridine) for the management of moderate to severe acute pain in adult patients in a hospital setting.","drugName":"Olinvyk","sentiment":"positive"},{"date":"2021-11-09","type":"earnings","headline":"Trevena Reports Third Quarter 2021 Financial Results","summary":"Trevena reported its third quarter 2021 financial results, including revenue of $1.4 million.","drugName":"","sentiment":"neutral"},{"date":"2021-08-09","type":"deal","headline":"Trevena Announces Collaboration with Pfizer to Develop and Commercialize Olinvyk in the US","summary":"Trevena announced a collaboration with Pfizer to develop and commercialize Olinvyk in the US.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-01-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-05-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPZkl5VjlwVGN3c08yUThral9YazZLVHZuUTNqc1cwUWY2b2NvTWI2VHNkWlo5Ung2M29PQ1pMNkNOWHAwcXB4bDJTQUlLbXNpOFFvUzhvNEhxU2lkMjlRV2YycTlfQWswYk1aN3RBWDYxZE9QelBKZ213TllNcUxoOXNkNkdBZS1Xd3RBODIxQzRxNFF6WXNReU84VmlrWmFYbGc?oc=5","date":"2025-01-15","type":"pipeline","source":"Investing.com","summary":"Trevena discontinues OLINVYK injection sales - Investing.com","headline":"Trevena discontinues OLINVYK injection sales","sentiment":"neutral"},{"date":"2025-01-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-11-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQOXBONWtSNWVPOWJkTU5IZXVxVWh0VlFTbTR2amgxa0xuNWVDdGxXSFFpZWJuNmNFZlNvMzkzQWs5RVdtSUluckx6RnowME14VU9oQ1BpOExocF9xNndNcG54dFRfancyTVl0Q09oUUZwX2JDeldtQlNxbzNfS1RiNDUxak9OcXpPbUI1UTN5NDVSNlk2dEwyaHZxYnpzV1UzcDJ2SlppRzJJZw?oc=5","date":"2024-11-15","type":"deal","source":"GuruFocus","summary":"ARMISTICE CAPITAL, LLC Acquires New Stake in Trevena Inc - GuruFocus","headline":"ARMISTICE CAPITAL, LLC Acquires New Stake in Trevena Inc","sentiment":"neutral"},{"date":"2024-11-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2024-11-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-10-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-10-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-09-19","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQLThZd2M4SGQ2LVhpSEFvbnp2ZzNzUDFyMUh4N0hMR1lWOHJtX2lER3pmYzRmbnFDVXpyOTFDZXI5SUZCLS1Zenc3MGN3VzdoVTVsank0NFlYanRmYUlXX3NrZ1o1Q3ljRXhwdHZ5THJhbEljWFBJR3ZHS25ianFDLUE4YUx3N2xaS3hhZ0k3akFtVmtPcnJSekR3aTBSSDNlQ2FmZF9TTjlvSXRLQzVEUGI4R2xfaHc0d3BRNQ?oc=5","date":"2024-08-08","type":"earnings","source":"Stock Titan","summary":"Trevena Reports Second Quarter 2024 Results and Provides Business Update - Stock Titan","headline":"Trevena Reports Second Quarter 2024 Results and Provides Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPWDZOTndtazA3cHFGU2Y5UlRqSlJHSFRlbU1RVV9jSzg4VXV0ZHRVY01QNHo5aGFvTUxETm1rYlZhaXRJUDEwcEZ4aWlIZC1uaXVaOXp5SGh6UmR0cTFES2ZIVFhlb2pGdmlrenQ1Mk9HOGF6SFQzOFdmdVZhS1pjMkxtR1BkWktGbGxjcE1ZSjdjSk0yckdRSUthVnU2aXctbHQtcWF2aklpLU1JM25RYm80TVdQYXBnQ1RxNTd2bVQ?oc=5","date":"2024-07-08","type":"pipeline","source":"Stock Titan","summary":"Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing - Stock Titan","headline":"Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPQXRnN2tkZWJKaGt6YUlka3VBRzI0enRzbzItQ0drdHlSYy1Kby1UV0NmZmd2OWl3R3RyS1F5WmdTRThUaHlVTmdJeUlMb2tnN1hCVmk3MmZIamxoXzdzY0tvdUVqM05hck1MekhFRzZ3Nm5QR0F3aTE1YXRnR001MTdTUEJUcXNOSWotcnNQQm45QXVMSTZuT2xXSjhyMUVJam51QVRtMTF6S3hFcmZIZWs1N05tZWFrWGtBVXVB?oc=5","date":"2024-01-02","type":"regulatory","source":"The Business Journals","summary":"Lab Notes: AstraZeneca enters into another $1B acquisition deal; FDA puts hold on Iovance drug study - The Business Journals","headline":"Lab Notes: AstraZeneca enters into another $1B acquisition deal; FDA puts hold on Iovance drug study","sentiment":"neutral"}],"patents":[{"drugName":"Olinvyk","drugSlug":"oliceridine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Johnson & Johnson","Merck & Co."],"therapeuticFocus":["Pain Management"],"financials":{"source":"sec_edgar","revenue":0,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":0,"period":"2017-12-31"},{"value":0,"period":"2017-09-30"},{"value":0,"period":"2017-06-30"},{"value":0,"period":"2017-03-31"},{"value":3750000,"period":"2016-12-31"},{"value":0,"period":"2016-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":16333000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-40289000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":32975000,"cashHistory":[],"totalAssets":40605000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.01,"previousClose":0.01,"fiftyTwoWeekHigh":1.38,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"0.001 - 1.38","fiftyDayAverage":0.01,"twoHundredDayAverage":0.2,"beta":0.52,"enterpriseValue":24119276,"forwardPE":0,"priceToBook":0,"priceToSales":0.02,"enterpriseToRevenue":44.17,"enterpriseToEbitda":-0.76,"pegRatio":0,"ebitda":-31748000,"ebitdaMargin":0,"freeCashflow":-16823750,"operatingCashflow":-27091000,"totalDebt":37564000,"debtToEquity":0,"currentRatio":2.42,"returnOnAssets":-62.4,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.5,"institutionHeldPercent":10,"sharesOutstanding":863788,"floatShares":858692,"sharesShort":59358,"shortRatio":1,"shortPercentOfFloat":7,"epsTrailing":-48.89,"epsForward":-19.85,"revenuePerShare":0.69,"bookValue":-27.27,"officers":[{"age":62,"name":"Ms. Carrie L. Bourdow","title":"President, CEO & Chairman"},{"age":67,"name":"Dr. Mark A. Demitrack M.D.","title":"Senior VP & Chief Medical Officer"},{"age":null,"name":"Dr. Howard A. Rockman M.D.","title":"Scientific Founder, Consultant and Member of Scientific Advisory Board"},{"age":48,"name":"Ms. Katrine  Sutton","title":"Principal Financial Officer & principal accounting officer"},{"age":59,"name":"Mr. Robert T. Yoder","title":"Senior VP, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer"},{"age":null,"name":"Mr. Michael  Catalano","title":"Vice President of Marketing"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.trevena.com","phone":"610 354 8840"}}